Biogen chairman: Alzheimer’s trial ‘extremely encouraging’ but ‘we need to do a lot more’
The latest clinical trial results for an Alzheimer’s treatment from drugmakers Biogen and Eisai are "an extremely encouraging first step but it’s only a first step. We need to do a lot more,” says Biogen Chairman Stelios Papadopoulos
from Top News & Analysis https://ift.tt/2zdR0Cs
from Top News & Analysis https://ift.tt/2zdR0Cs
0 Response to "Biogen chairman: Alzheimer’s trial ‘extremely encouraging’ but ‘we need to do a lot more’"
Post a Comment